title: Evidence for direct interaction of ketamine with alpha 1- and beta 2-adrenoceptors.
abstract: 1. Ketamine has a number of effects that suggest that it may interact with alpha- and beta-adrenoceptors. To date, the experimental evidence for this has been indirect and has been based on physiological studies using competitive blocking agents. In the present study we sought to determine from receptor binding studies whether ketamine binds directly to alpha- and beta-adrenoceptors. 2. Membrane preparations of alpha 1- and beta 2-adrenergic binding sites were obtained from urinary bladder and urethrae of sheep. These binding sites were characterized by saturation analyses using [3H]-prazosin for alpha 1-adrenoceptor binding sites and [125I]-cyanopindolol (CYP) for the beta 2-adrenoceptor binding sites. The receptors were further characterized by displacement studies using selective and non-selective antagonists. 3. Studies in which ketamine was used to displace [3H]-prazosin revealed a Kd of 3.40 +/- 1.23 x 10(-3) mol/L for ketamine binding to alpha 1-adrenoceptors. Displacement studies of [125I]-CYP by ketamine showed a Kd of 0.35 +/- 0.03 x 10(-3) mol/L for ketamine binding to beta 2-adrenoceptors. 4. We conclude that ketamine interacts directly with both alpha 1- and beta 2-adrenoceptors and that such interactions probably explain the reported effects of this agent on the vasculature and the bronchial tree.
authors.affiliation: University Department of Surgery, Prince Henry's Hospital, Sydney, New South Wales, Australia.
authors.forename: R K
authors.initials: RK
authors.lastname: Bevan
authors.forename: M A
authors.initials: MA
authors.lastname: Rose
authors.forename: K A
authors.initials: KA
authors.lastname: Duggan
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D004347:Drug Interactions; D018691:Excitatory Amino Acid Antagonists / Q000378:metabolism* / Q000494:pharmacology*; D007457:Iodine Radioisotopes; D020120:Iodocyanopindolol; D007649:Ketamine / Q000378:metabolism* / Q000494:pharmacology*; D007700:Kinetics; D010869:Pindolol / Q000031:analogs & derivatives / Q000378:metabolism; D011224:Prazosin / Q000378:metabolism; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects* / Q000378:metabolism*; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects* / Q000378:metabolism*; D012756:Sheep; D013268:Stimulation, Chemical; D013379:Substrate Specificity; D014316:Tritium
chemical_list: D000317:Adrenergic alpha-Antagonists; D018691:Excitatory Amino Acid Antagonists; D007457:Iodine Radioisotopes; D018340:Receptors, Adrenergic, alpha-1; D018343:Receptors, Adrenergic, beta-2; D014316:Tritium; D007649:Ketamine; D020120:Iodocyanopindolol; D010869:Pindolol; D011224:Prazosin